In a Jan. 4 research note, Dawson James Securities Inc. Senior Healthcare Analyst Jason Kolbert commented that clinical and commercial stage biopharmaceutical company Sorrento Therapeutics Inc. (SRNE:NASDAQ) announced that "initial testing of COVISTIX on recombinant N proteins successfully demonstrated its ability to detect the Omicron variant, in addition to detecting the original SARS-CoV-2 virus and its other major variants such as the delta and delta-plus strains."
Kolbert advised that Dawson James Securities has an optimistic view on Sorrento which is predicated upon the firm's ability to successfully develop and commercialize both therapeutics and its rapid antigen detection COVISTIX tests for SARS-CoV-2 and prevailing variants of concern and specifically Omicron.
The Dawson James report mentioned that Sorrento has investigated COVISTIX's capability to detect the Omicron variant in comparison with other approved COVID-19 virus rapid antigen tests. The analyst stated that initial results from studies show that "COVISTIX was able to detect the Omicron N protein at a significantly lower level than other commercially available tests."
Sorrento is now able to produce 30 million COVISTIX tests per month and is expanding its U.S. manufacturing capacity. The firm expects that its fully automated U.S. facility will be ready to make 6 million COVISTIX units each month in Q1/22. If the demand worldwide warrants it, the company is making plans to produce over 100 million tests per month in 2022.
The analyst noted that on the therapeutics side of the business, Sorrento also announced "the publication of a series of novel SARS-CoV-2 main protease (MPRO) inhibitors for the potential treatment of COVID-19 patients infected with SARS-CoV-2 variants of concern, including omicron."
In addition, Dawson James stated that Sorrento's subsidiary Scilex Holding and Vickers Vantage Corp. The firms signed a letter of intent proposing a business combination valuing Scilex at about $1.5 billion on a pre-transaction equity basis. If the deal goes forward, it would provide Sorrento with gross proceeds of up to $140 million.
The report explained that Scilex is focused on developing and commercializing non-opioid medications for acute and chronic pain. The company's ZTLIDO (lidocaine topical system) 1.8%, is an FDA approved non-opioid prescription lidocaine topical product used for relieving associated with postherpetic neuralgia, a painful condition often brought on by shingles occurrences. The analyst noted that ZTLIDO sales are continuing to grow around 35% annually.
The report from Dawson James Securities, Inc. indicated that its valuation models for Sorrento are based highly upon the company's success in developing and commercializing COVID tests and therapeutics. The research firm advised that it arrived at its valuation for the firm using equal-weighted averages of its therapeutic, free cash flow, discounted EPS and sum of the parts calculations taking into account estimated fully diluted year-end share count along with expected capital raises.
Dawson James Securities has a "Buy" rating and a $18.00 price target for Sorrento Therapeutics. The company's shares trade on the Nasdaq Exchange under the symbol "SRNE" and last closed for trading at $4.73 on Tuesday, Jan. 4, 2021.
Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
Disclosures for Dawson James Securities Inc., Sorrento Therapeutics Inc., Jan. 4, 2022
Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC"). The Firm does not make a market in the securities of the subject company(s). The Firm has NOT engaged in investment banking relationships with SRNE in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has NOT received any other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.
Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director, or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of December 31, 2021, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts, or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.
Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.
Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.
The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.
Analyst Certification: The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.
